Rheumatoid Arthritis Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Rheumatoid Arthritis pipeline constitutes 75+ key companies continuously working towards developing 80+ Rheumatoid Arthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Rheumatoid Arthritis Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market.

The Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Get a Free Sample PDF Report to know more about Rheumatoid Arthritis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key takeaways from the Rheumatoid Arthritis Pipeline Report:
• Companies across the globe are diligently working toward developing novel Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years.
• Rheumatoid Arthritis companies working in the treatment market are Eli Lilly and Company/Incyte Corporation, AbbVie, Cyxone, IGM Biosciences, Regeneron/Sanofi, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others, are developing therapies for the Rheumatoid Arthritis treatment
• Emerging Rheumatoid Arthritis therapies in the different phases of clinical trials are- OLUMIANT (barticinib), RINVOQ (upadacitinib), Rabeximod (Rob 803), Imvotamab, Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others are expected to have a significant impact on the Rheumatoid Arthritis market in the coming years.
• In July 2026, Precision immunology company Scipher Medicine has announced its merger with Chemomab Therapeutics, following the identification of the Israeli biotech's liver disease candidate as a strong strategic fit with Scipher's expertise. The combined company will continue operating under the Scipher name while utilizing Chemomab's Nasdaq listing, with the stock ticker changing to "SCIP." The merged entity will primarily focus on advancing nebokitug, Chemomab's anti-CCL24 antibody, which is slated to enter a Phase II clinical trial for the treatment of rheumatoid arthritis.
• In July 2026, Emerging and investigational therapies for rheumatoid arthritis are expanding the treatment landscape, with Janus kinase (JAK) inhibitors and Bruton's tyrosine kinase (BTK) inhibitors showing significant potential to reduce inflammation and improve disease management. In addition, innovative approaches such as vagus nerve stimulation are under investigation as potential therapies to enhance clinical outcomes and improve patients' quality of life.
• In June 2026, Generic drug manufacturer Aurobindo Pharma has secured final approval from the U.S. Food and Drug Administration (FDA) for its Tofacitinib Tablets USP, available in 5 mg and 10 mg strengths. The approved product has been confirmed as bioequivalent and therapeutically equivalent to Xeljanz Tablets (5 mg and 10 mg), marketed by PF Prism C.V. Manufacturing will take place at APL Healthcare's Unit IV, a subsidiary of Aurobindo Pharma, with commercial launch planned immediately following the approval.
• In June 2026, According to the latest guidance from the European Alliance of Associations for Rheumatology (EULAR), the increasing availability of biosimilar disease-modifying antirheumatic drugs (DMARDs) and the introduction of generic Janus kinase inhibitors (JAK inhibitors) have significantly influenced recommendations on treatment sequencing for patients with rheumatoid arthritis (RA). Published in the Annals of the Rheumatic Diseases, the 2025 EULAR recommendations for managing RA with synthetic and biologic DMARDs represent the most streamlined version of the guidance so far, reducing the number of recommendations from 11 to 9. The update was undertaken three years after the 2022 revision to incorporate new evidence from strategic clinical trials and emerging safety data related to JAK inhibitors, prompting a reevaluation of the current therapeutic approach.
• In January 2026, SetPoint Medical, a biotechnology company focused on innovative treatments for chronic autoimmune conditions, announced the publication of results from its RESET-RA study in Nature Medicine. This pivotal, double-blind, randomized, sham-controlled trial assessed the safety and effectiveness of the SetPoint System, an implantable neuroimmune modulation device that targets the vagus nerve. The therapy is designed for adults with moderate to severe rheumatoid arthritis (RA) who have an inadequate response to, or are unable to tolerate, currently available advanced RA treatments, including biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs).
• In September 2025, Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for children aged six years and older weighing at least 40 kg with moderate to severe plaque psoriasis (PsO) who are eligible for systemic therapy or phototherapy, as well as for active psoriatic arthritis (PsA). This approval marks TREMFYA® as the first and only IL-23 inhibitor authorized for these pediatric indications, expanding upon its prior FDA approvals for adults with moderate to severe plaque PsO in 2017 and active PsA in 2020.
• In April 2025, The European Medicines Agency (EMA) granted approval for Cullinan Therapeutics' clinical trial application of CLN-978, a potential treatment for rheumatoid arthritis (RA). This Phase I open-label study will enroll patients with active, treatment-resistant RA, as defined by the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria. The trial is designed to evaluate the drug's pharmacokinetics, pharmacodynamics, safety profile, and its effect on disease activity.
• In February 2025, AnaptysBio's Phase IIb trial evaluating rosinilimab for rheumatoid arthritis (RA) has delivered promising results, with some patients achieving the highest recorded response rates by week 14. Remarkably, 69% of participants attained low disease activity. The U.S.-based company presented findings from its randomized RENOIR trial (NCT06041269), which assessed the safety and tolerability of rosinilimab in moderate-to-severe RA patients previously treated with conventional disease-modifying drugs. The study successfully met its primary endpoint, demonstrating a statistically significant improvement in DAS28-CRP scores compared to placebo, reinforcing rosinilimab's potential as an effective RA treatment.
• In December 2024, XBiotech's stock price dropped significantly after the company announced the termination of its clinical program in rheumatological diseases. This decision follows the evaluation of a Phase II trial for its arthritis treatment, Natrunix, which did not meet its primary endpoint. The Austin, Texas-based biotech firm saw a 27% decline in stock value after the trial (NCT05363917) revealed substantial irregularities, making it difficult to draw definitive conclusions from the study results.
• In October 2024, SetPoint Medical has received an investigational device exemption (IDE) from the US Food and Drug Administration (FDA), allowing it to start a clinical trial to test its modulation platform in relapsing-remitting multiple sclerosis (RRMS) patients. The multicenter, randomized, double-blind, sham-controlled pilot study will take place in the US and is set to begin in 2025. The US-based company plans to enroll 60 patients with the autoimmune disorder for the trial.
• In July 2024, Navidea Biopharma has decided to discontinue its rheumatoid arthritis (RA) program following unsatisfactory findings from an exploratory analysis of the NAV3-33 trial. The Phase III study (NCT05246280), which included 523 participants, aimed to validate the effectiveness of intravenous (IV) Lymphoseek (Tc 99m tilmanocept) imaging in predicting clinical outcomes in RA patients starting anti-tumor necrosis factor alpha (TNFα) therapy.
• In July 2024, Dutch biotech firm Citryll has completed subject dosing in the repeat-dose phase of its Phase I clinical trial for CIT-013, an anti-inflammatory drug candidate. This first-in-human study focuses on evaluating the safety and tolerability of the antibody. In the trial's part D segment, the safety and tolerability of CIT-013 are further assessed through repeat dosing in a group of nine rheumatoid arthritis (RA) patients and three healthy volunteers.

Rheumatoid Arthritis Overview
Rheumatoid Arthritis (RA) is a chronic autoimmune disorder in which the immune system mistakenly attacks the joints, causing inflammation, pain, stiffness, and swelling. Over time, it can lead to joint damage, deformities, and reduced mobility. RA can also affect other organs, including the heart, lungs, and eyes. Early diagnosis and treatment are essential to manage symptoms, slow disease progression, and improve quality of life.

Explore the latest Rheumatoid Arthritis pipeline insights 2026, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Rheumatoid Arthritis Clinical Trials
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Emerging Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:
• OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation
• RINVOQ (upadacitinib): AbbVie
• Rabeximod (Rob 803): Cyxone
• Imvotamab: IGM Biosciences
• Sarilumab (Kevzara): Regeneron/Sanofi
• Baricitinib: Eli Lilly and Company
• Certolizumab pegol: UCB BIOSCIENCES GmbH
• Upadacitinib: AbbVie
• Tofacitinib: Pfizer
• Sarilumab SAR153191 (REGN88): Sanofi
• GenaKumab: Changchun GeneScience Pharma
• AIN457: Novartis
• Etanercept: Istituto Giannina Gaslini

Rheumatoid Arthritis Route of Administration
Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Rheumatoid Arthritis Molecule Type
Rheumatoid Arthritis Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Rheumatoid Arthritis Pipeline Therapeutics Assessment
• Rheumatoid Arthritis Assessment by Product Type
• Rheumatoid Arthritis By Stage and Product Type
• Rheumatoid Arthritis Assessment by Route of Administration
• Rheumatoid Arthritis By Stage and Route of Administration
• Rheumatoid Arthritis Assessment by Molecule Type
• Rheumatoid Arthritis by Stage and Molecule Type

DelveInsight's Rheumatoid Arthritis Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Rheumatoid Arthritis product details are provided in the report. Download the Rheumatoid Arthritis pipeline report to learn more about the emerging Rheumatoid Arthritis therapies
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key companies in the Rheumatoid Arthritis Therapeutics Market include:
Key companies developing therapies for Rheumatoid Arthritis are - Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., and others.

Rheumatoid Arthritis Pipeline Analysis:
The Rheumatoid Arthritis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Rheumatoid Arthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rheumatoid Arthritis Treatment.
• Rheumatoid Arthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rheumatoid Arthritis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Rheumatoid Arthritis drugs and therapies
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Rheumatoid Arthritis Pipeline Market Drivers
• Rising prevalence of arthritis and other joint disorders, rising combinational therapy of biologics for the treatment of Rheumatoid Arthritis, rich emerging pipeline, acceptance of biosimilars for treatment of Rheumatoid Arthritis are some of the important factors that are fueling the Rheumatoid Arthritis Market.

Rheumatoid Arthritis Pipeline Market Barriers
• However, high cost of biologics, low adherence to the drugs, lack of daily assessment of RA • Delay in RA diagnosis and other factors are creating obstacles in the Rheumatoid Arthritis Market growth.

Scope of Rheumatoid Arthritis Pipeline Drug Insight
• Coverage: Global
• Key Rheumatoid Arthritis Companies: Eli Lilly and Company/Incyte Corporation, AbbVie, Cyxone, IGM Biosciences, Regeneron/Sanofi, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others
• Key Rheumatoid Arthritis Therapies: OLUMIANT (barticinib), RINVOQ (upadacitinib), Rabeximod (Rob 803), Imvotamab, Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others
• Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies
• Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.